Plug Power Inc vs Repligen Corporation Common Stock — how do they compare? Plug Power Inc trades at $1.43 (market cap $2.18B), while Repligen Corporation Common Stock trades at $178.18 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 5.1× Plug Power Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 42 Days and Repligen Corporation Common Stock for 0 Days on average.
| PLUG | RGEN | |
|---|---|---|
Market Cap | $2.18B | $11.14B |
Volume | 58,569,311 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $4.14 | $194.57 |
52-Week Low | $1.45 | $102.87 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $3.05B | $11.02B |
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.45, down 10.49% today, reflecting ongoing operational challenges. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -220.59% net income margin and negative cash flow. Recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels, but the company continues to miss earnings expectations consistently.
Despite analyst consensus favoring Buy ratings (44.73%), PLUG faces significant execution risks with negative profitability and high cash burn. The $3.33 price target suggests potential upside if green hydrogen adoption accelerates, but investors must weigh substantial operational losses against long-term growth prospects in the clean energy sector.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →